Berkeley Lovelace Jr. is a health and medical reporter for NBC News. He covers the Food and Drug Administration, with a special focus on Covid vaccines, prescription drug pricing and health care. He previously covered the biotech and pharmaceutical industry with CNBC.
Novo Nordisk said Friday it settled two lawsuits against two businesses claiming to offer compounded versions of its blockbuster drugs Ozempic and Wegovy. The drugmaker has filed a total of 12 lawsuits against clinics, med spas and compounding pharmacies in the U.S. that claim to offer semaglutide, the active ingredient in Ozempic and Wegovy.
They are also permanently banned from using any Novo Nordisk trademarks or logos in their products as well as any 'misleading' advertising, the drugmaker said. Both businesses will be given a year to make the changes. The settlements come as states have been cracking down on compounded versions of the drug, which they say may contain other ingredients that are not approved by the FDA.